Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: TG6050-en

Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

Eligibility PEA-PME

Published 6 February 2025
Categorized as 2025, Press release, TG6050-en

Transgene To Participate in the Biomed Forum Investor Conference

BIOMED FORUM

Published 21 January 2025
Categorized as 2025, dates, dates, Press release, TG6050-en, TG6050-en

Transgene Announces Financial Calendar for 2025

calendrier 2025

Published 14 January 2025
Categorized as 2025, dates, dates, Press release, TG6050-en

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment

L.Fend, et al. ESMO 2024  Abstract available on the CICON website – Download the abstract and the poster

Published 10 September 2024
Categorized as 2024, Invir.IO, Publication, TG6050-en

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

F. Azar et al. Journal for ImmunoTherapy of Cancer July 2024 Article available on JITC website

Published 27 August 2024
Categorized as 2024, Publication, TG6050-en

Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC

TG6050

Published 27 August 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release, TG6050-en

Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer

First patient dosed in Phase I trial evaluating TG6050 15

Published 10 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Invir.IO, Press release, TG6050-en

Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR

Preclinical results showing TG6050 induces tumor regression by activating innate and adaptive immune responses 15

Published 17 April 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release, TG6050-en

TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses

JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

Published 16 April 2023
Categorized as 2023, Invir.IO, Publication, TG6050-en

Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023

Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15

Published 15 March 2023
Categorized as 2023, dates, Press release, TG4001, TG4050, TG6002, TG6050-en

Posts pagination

Page 1 Page 2 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu